David Guyer, co-founder and chief executive of Ophthotech Corporation, has joined the board of directors of ThromboGenics NV which is rolling out a new product for the treatment of vitreomacular traction in the US. Dr Guyer also co-founded and served as CEO of Eyetech Pharmaceuticals Inc which developed the first US approved anti-VEGF pharmaceutical treatment for wet age-related macular degeneration. Eyetech was acquired by OSI Pharmaceuticals Inc in 2005. Dr Guyer received his Bachelor of Science degree from Yale College and his medical degree from Johns Hopkins Medical School.
ThromboGenics announced the appointment on 20 December 2013.
Copyright 2013 Evernow Publishing Ltd